For instance, NRF2 inhibitors, such as Brusatol and Brucein D, promote ubiquitination and proteasomal degradation of NRF2, enhancing chemosensitivity in cancers like AML, endometrial cancer, and pancreatic ductal adenocarcinoma. Here, NFE2L2 is linked to acute myeloid leukemia.